In ovarian cancer, the combination of the FAK inhibitor TAE-226 with docetaxel was tested for its effects on cytotoxicity, apoptosis, angiogenesis, and cell proliferation in taxane-sensitive and taxane-resistant cell lines. Here, PTK2 is linked to ovarian cancer.